Action mechanism of bis(allixinato)oxovanadium(IV) as a novel potent insulin-mimetic complex: regulation of GLUT4 translocation and FoxO1 transcription factor-Reference-Cited by-同舟云学术

Action mechanism of bis(allixinato)oxovanadium(IV) as a novel potent insulin-mimetic complex: regulation of GLUT4 translocation and FoxO1 transcription factor

Published:2007-09-06 Issue:8 Volume:12 Page:1275-1287
ISSN:0949-8257
Container-title:JBIC Journal of Biological Inorganic Chemistry
language:en
Short-container-title:J Biol Inorg Chem

Author:

Hiromura Makoto,Nakayama Akihiro,Adachi Yusuke,Doi Miyuki,Sakurai Hiromu

Publisher

Springer Science and Business Media LLC

Subject

Inorganic Chemistry,Biochemistry

Link

http://link.springer.com/content/pdf/10.1007/s00775-007-0295-x.pdf

Reference68 articles.

1. Wild S, Roglic G, Green A, Sicree R, King H (2004) Diabetes Care 27:1047–1053

2. Kuzuya T, Nakagawa S, Satoh J, Kanazawa Y, Iwamoto Y, Kobayashi M, Nanjo K, Sasaki A, Seino Y, Ito C, Shima K, Nonaka K, Kadowaki T (2002) Diabetes Res Clin Pract 55:65–85

3. Alexandraki K, Piperi C, Kalofoutis C, Singh J, Alaveras A, Kalofoutis A (2006) Ann N Y Acad Sci 1084:89–117

4. Muoio DM, Newgard CB (2006) Annu Rev Biochem 75:367–401

5. Herman MA, Kahn BB (2006) J Clin Invest 116:1767–1775

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hydrazone-flavonol based oxidovanadium(V) complexes: Synthesis, characterization and antihyperglycemic activity of chloro derivative in vivo;Journal of Inorganic Biochemistry;2024-09

2. Synthesis and crystal structure of bis(2-aminobenzimidazolium) catena-[metavanadate(V)];Acta Crystallographica Section E Crystallographic Communications;2024-06-18

3. Identification of a 10-mer peptide from the death domain of MyD88 which attenuates inflammation and insulin resistance and improves glucose metabolism;Biochemical Journal;2024-02-13

4. Misinterpretations in Evaluating Interactions of Vanadium Complexes with Proteins and Other Biological Targets;Inorganics;2021-02-09

5. FoxO1 signaling as a therapeutic target for type 2 diabetes and obesity;European Journal of Pharmacology;2021-01